Envoy Medical, Inc. (COCH) · Oct 27, 2026 · Other events
1-for-10 reverse split — 1-for-10 ratio; $1.00 minimum bid requirement
Envoy Medical’s reverse stock split addresses Nasdaq’s $1 minimum bid rule, but adds no funding or new Acclaim milestone.
Envoy Medical is a clinical-stage hearing-technology company trying to move its fully implanted Acclaim cochlear implant through a rolling FDA application and pivotal trial; it submitted the second of four planned PMA modules on October 12, with the final clinical module targeted for the second quarter of 2027.
This filing fixes a listing problem, not the product-development story. The company implemented a 1-for-10 reverse split to address Nasdaq’s $1.00 minimum bid requirement. It consolidates shares and proportionately adjusts warrants, convertibles, and equity-plan shares, while leaving the authorized share count unchanged. 〔0〕
The action is largely procedural and already known. Stockholders approved the reverse-split authority on October 12, and the company announced the specific 1-for-10 ratio and October 26 effective date on October 22. 〔1〕 That makes this 8-K confirmation rather than a new financing, clinical result, FDA milestone, or change to the Acclaim timeline.
It preserves access to Nasdaq but does not strengthen operating liquidity. The split may help the company remain listed and potentially broaden the pool of institutions able to hold the stock, but the filing provides no proceeds, runway extension, or evidence that the Acclaim program is closer to approval. The separate compliance risk remains relevant: the company’s proxy identified November 16, 2026 as the deadline to regain compliance, with delisting proceedings possible if it failed.
Bottom line: This is a necessary capital-markets housekeeping step that protects the company’s listing status, but it does not advance Envoy Medical’s core Acclaim commercialization story. Its significance is therefore limited and mostly already reflected in the prior shareholder approval and announcement.
Nasdaq compliance deadline, November 16, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!